Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Porton Pharma Solutions Ltd (Porton) is a contract development and manufacturing organization that provides small-molecule active pharmaceutical ingredients, dosage forms and biologics manufacturing services. The company offers active pharmaceutical ingredients (API) process development, manufacturing, technology platform, quality studies and analytical research and development and CMC registration support services. Porton also provides small molecules contract development and manufacturing organization services, and end-to-end solutions such as early development, late development, commercial supply, and analytical solution. It operates research and development centers in China, manufacturing facilities in China and process technology centers in the US. Porton is headquartered in Chongqing, China.
Headquarters
China
Address
No. 7 Yuntu Road, Chongqing, 400714
Website
www.portonpharma.com
Telephone
86 23 65936900
No of Employees
4,359
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
300363 (SHE)
Revenue (2024)
$475.9M
13.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
133.5%
(2024 vs 2023)
Market Cap*
$1.4B
Net Profit Margin (2024)
XYZ
129.5%
(2024 vs 2023)
* As of and is in US$
Porton Pharma Solutions Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Active Pharmaceutical Ingredients | Small Molecules Contract Development and Manufacturing Organization Services |
| Peptides | Drug Substance Capability |
| Oligonucleotides | Drug Substance Capacity |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In March, the company partnered with Hubei Jianxiang Bioscience to build a comprehensive peptide drug CDMO platform. |
| 2024 | Contracts/Agreements | In December, the company partnered with Aojin Life Sciences to provide CDMO services for the CMC research and GMP production of XDC conjugate drugs, targeting IND filings in China and the US. |
| 2024 | Contracts/Agreements | In December, the company signed an agreement with Dragon Sail Pharmaceutical (Shanghai) Co., Ltd. for the research, development, production, and supply chain integration of antibody-drug conjugates. |
Competitor Comparison
| Key Parameters | Porton Pharma Solutions Ltd | Shandong Xinhua Pharmaceutical Co Ltd | Zhejiang Huahai Pharmaceutical Co Ltd | Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd | Viva Biotech Holdings |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Chongqing | Zibo | Taizhou | Tianjin | Shanghai |
| State/Province | Chongqing | Shandong | Zhejiang | Tianjin | Shanghai |
| No. of Employees | 4,359 | 7,240 | 8,797 | 3,890 | 2,169 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ju Nianfeng | General Manager; Chairman | Executive Board | 2018 | 54 |
| Bai Yinchun | Chief Operating Officer; Senior Vice President; Director | Executive Board | 2026 | 53 |
| Chen Hui | Deputy General Manager; Chief Financial Officer | Senior Management | 2022 | 47 |
| Pi Wei | Deputy General Manager; Secretary | Senior Management | 2022 | 39 |
| Meng Fan | Deputy General Manager | Senior Management | 2025 | 42 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer